PDL BioPharma, Inc. (NASDAQ:PDLI)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Recs

0
Player Avatar marketprofile01 (63.64) Submitted: 5/14/2011 7:11:38 PM : Outperform Start Price: $5.76 PDLI Score: +13.47

beaupost beat

Report this Post Reply

Featured Broker Partners


Advertisement